Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting.
Stephen J FreedlandAgnes HongNader El-ChaarSharanya MurtyKrishnan RamaswamyAnna D CoutinhoDavid NimkeAlicia K MorgansPublished in: Prostate cancer and prostatic diseases (2022)
Black and White men with presumed chemotherapy-naïve mCRPC had similar PSA responses when treated with enzalutamide, but Black men had better cPFS than White men. Further research is warranted to validate these findings.